30 closest matches · ranked by relevance
Adult Diffuse Large Cell Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma · Stage IV Adult Diffuse Large Cell Lymphoma
Primary: Objective Tumor Response — 0 participants
Thymoma
Primary: Percent of Patients With Objective Response — 7.1 percentage of participants
Lymphoma
Primary: Event-free Survival — 76 percentage of patient
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
Lymphoma, B-Cell
Primary: Objective Response Rate (ORR) Using International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma as Assessed by Independent Central Review — 42.9…
Diffuse Large B-cell Lymphoma
Primary: 1-year Progression-free Survival — 31 Participants
Lymphoma, Large Cell, Diffuse · Lymphoma, Mixed Cell, Diffuse · Primary Mediastinal Large B-Cell Lymphoma
Primary: Progression-free Survival — 72 Percent
Diffuse Large B-Cell Lymphoma
Primary: Objective Response Rate (ORR) — 47.5; 46.2; 43.6 Percentage of participants — p=0.5543
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Lymphoma
Primary: Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) — 87 percentage of participants
Lymphoma
Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants
Primary Inoperable Thymoma · Local Recurrent Thymoma
Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Mediastinal Large B-cell Lymphoma · Richter Syndrome
Primary: Objective Response Rate (ORR) Based on International Working Group (IWG) Response Assessment Criteria Per Independent Central Review — 45.3; 13.0 Percentage of…
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Relapsed/Refractory Aggressive B-cell Lymphomas
Primary: Maximum Tolerated Dose (MTD) of MEDI-551 — NA; NA mg/kg
Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma Activated B-Cell Type · Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Primary: Maximum Tolerated Dose (MTD) — 100 mg TAK-659
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Primary Mediastinal Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Objective Response Rate — 3 Participants
Large B Cell Lymphoma
Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519
Primary Mediastinal Large B Cell Lymphoma
Primary: Overall Objective Response Rate in Patients With Relapsed or Refractory PMLBCL — 11; 1; 1; 1 Participants
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Diffuse Large B-cell Lymphoma
Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276
High-risk Diffuse Large B-Cell Lymphoma
Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants
Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma · Peripheral T-Cell Lymphoma
Primary: Progression-free Survival After ASCT — 0.58; 0.77; 0.62 proportion of participants
Lymphoma
Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Lymphoma
Primary: Disease-free Survival at 1 Year — 0.818; 0.90 years
Peripheral T Cell Lymphoma
Primary: Efficacy: Complete Response Rate — 11 Participants — p=.1